Status: Available
Individual Patient Compassionate Use of Mirdametinib
This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee, and applicable competent authority approval.
Trial details
Age: 2+Biological sex: AllType: Expanded AccessSponsor: SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, GermanyUpdated: May 8, 2026
Eligibility criteria
Patient has a serious, debilitating or life-threatening medical condition that c... [+1]